About Innoviva
Innoviva is a publicly listed company based in Brisbane (United States) founded in 1996. Respiratory prescription drugs are developed and in-licensed for COPD treatment. The company has 127 employees. Innoviva has completed 2 acquisitions, including Entasis Therapeutics and La Jolla Pharmaceutical. Its chief executive, as recorded, is Pavel Raifeld. Innoviva offers products and services including Royalty Portfolio and Critical Care Platform. Its focus areas include Life Sciences, Pulmonology, Drugs and COPD and Asthma. Its legal entity is THERAVANCE INC. Its competitors include Landos Biopharma, Theron Pharma and Stromatis Pharma; 2 of its 3 listed competitors have raised funding.
Company details
Innoviva was founded in 1996 in Brisbane, United States, within the pharmaceutical sector focused on respiratory conditions. Prescription drugs are developed through in-licensing partnerships with Glaxo Group. Operations center on inhaled therapies, including RelvarBreoEllipta as a combination respiratory drug and AnoroEllipta as a dual bronchodilator, both targeted at managing chronic obstructive pulmonary disease.
- Annual Revenue$425.13 M (USD)14.12as on Dec 31, 2025
- Net Profit$271.17 M (USD)1059.22as on Dec 31, 2025
- EBITDA$203.97 M (USD)-1.33as on Dec 31, 2025
- Latest Funding Round$261M (USD), Post-IPO
Apr 2022
- InvestorsGoldman Sachs
& 1 more
- Employee Count127
- Investments & AcquisitionsEntasis Therapeutics
& 1 more
Products & Services of Innoviva
Innoviva offers a comprehensive portfolio of products and services, including Royalty Portfolio and Critical Care Platform.
Manages royalties from healthcare products and therapies
Supports growth in infectious disease treatments and assets
Funding Insights of Innoviva
- Total Rounds 2
- Last Round Post-IPO — $261M
- First Round $192.5M
(Aug 2017)
- Investors Count 2
All 2 funding rounds of Innoviva with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $261M | Post-IPO | – | – | |
| Aug 2017 | $192.5M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Innoviva
Innoviva has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Goldman Sachs and Moelis & Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment banking services are delivered across multiple financial sectors. | 1869 | goldmansachs.com | New York, United States | |
Advisory services in M&A, restructuring, and capital raising are offered. | 2007 | moelis.com | New York, United States |
Investor details for Innoviva
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Innoviva
15 people are tracked at Innoviva (8 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 127.
| Name | Role | Group |
|---|---|---|
Pavel Raifeld | CEO | Leadership |
Marianne Zhen | Chief Accounting Officer | Leadership |
Marcie Cain | Chief People Officer | Leadership |
Steve Basso | Chief Financial Officer | Leadership |
Matt Ronsheim | President, IST | Leadership |
Austin Rory Hackett, M.D. | Vice President, Business Development | Leadership |
Narciso Pacis Jr. | Senior Director of Accounting and Finance | Leadership |
Christine Coyne | Chief Commercial Officer, IST | Leadership |
Odysseas Kostas | Chair | Board & advisors |
Jules Haimovitz | Director | Board & advisors |
Mark Dipaolo | Director | Board & advisors |
Sarah J. Schlesinger | Director | Board & advisors |
Deborah Birx | Independent Board Director, Chair Audit Committee | Board & advisors |
Sapna Srivastava | Director | Board & advisors |
Clarissa Lau | Senior General Accountant | Team |
Complete people profiles for Innoviva
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Innoviva
Innoviva is a publicly listed company on the NASDAQ with ticker symbol INVA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Oct 2004
- Listed onNASDAQ: INVA
- Listed entityInnoviva, Inc.
- Exchange sectorHealth technology
- ISINUS45781M1018
- Share price$20.74 (-3.31% on the day) · 2026-10-13
- Market capitalisation$1.50B
- Price to earnings5.1
- EPS (diluted, trailing year)$4.10
- Volume (last session)811,564
Financials of Innoviva
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $425.1M | $271.2M | $204.0M |
| 2024 | $372.5M | $23.4M | $206.7M |
| 2023 | $324.3M | $179.7M | $149.6M |
| 2022 | $345.2M | $213.9M | $226.5M |
| 2021 | $405.7M | $265.9M | $392.2M |
Detailed financial statements for Innoviva
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Innoviva
Innoviva has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Entasis Therapeutics and La Jolla Pharmaceutical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of therapies for treating hemochromatosis & beta thalassemia | lajollapharmaceutical.com | San Diego, United States | 1989 | Jul 2022 | $149M | |
Small molecules for drug-resistant bacterial infections are developed. | entasistx.com | Waltham, United States | 2015 | May 2022 | •••• |
Complete acquisition details for Innoviva
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Innoviva
6 dated milestones of Innoviva across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Innoviva is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $192.5M.
- Funding Latest funding round, Post-IPO, of $261.0M.
- Acquisition Acquires Entasis Therapeutics.
- Acquisition Acquires La Jolla Pharmaceutical.
Competitors of Innoviva
Innoviva has 3 listed competitors in our database, 2 of them funded. They include Landos Biopharma, Theron Pharma and Stromatis Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| landosbiopharma.com | 2016 | Blacksburg, United States | $70.26M | 28 | Small molecule therapeutics for autoimmune diseases are developed. | |
| theronpharma.com | 2008 | Sunnyvale, United States | $2.21M | Specialty drugs for chronic respiratory diseases are developed. | ||
| stromatis.com | 2016 | Athens, United States | Drugs for cystic fibrosis treatment are developed by Stromatis Pharma. |
Detailed competitors of Innoviva
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Innoviva
The website of Innoviva (inva.com) receives about 6.2K visits a month.
- Monthly visits6.2K
▼ 16% vs previous month
Websites whose visitors overlap most with Innoviva. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sofinnova.com | 100% | #3,189,821 | View details | ||
inovivalife.com | inovivalife.com | 30% | #1,833,500 | – |
Top companies in Pulmonology
3 companies that operate in the same segment as Innoviva (Pulmonology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | 329 | ||
Portable oxygen concentrators are supplied for respiratory therapy needs. | 2001 | Goleta, California, United States | USD 51.65 M | USD 348.67 M | 766 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Innoviva
Complete news archive for Innoviva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Innoviva
Innoviva was founded in 1996 and raised its 1st funding round 21 years after it was founded.
Innoviva is headquartered in Brisbane, United States. It is registered at Brisbane, California, United States.
Pavel Raifeld is the CEO of Innoviva, as recorded in our data.
Innoviva has 127 employees.
Annual revenue of Innoviva is $425.13M as on Dec 31, 2025.
Innoviva was founded in 1996 in Brisbane, United States, within the pharmaceutical sector focused on respiratory conditions. Prescription drugs are developed through in-licensing partnerships with Glaxo Group. Operations center on inhaled therapies, including RelvarBreoEllipta as a combination respiratory drug and AnoroEllipta as a dual bronchodilator, both targeted at managing chronic obstructive pulmonary disease.
Innoviva's top competitors include Landos Biopharma, Theron Pharma and Stromatis Pharma.
Innoviva offers Royalty Portfolio and Critical Care Platform.
Yes, Innoviva is publicly traded on NASDAQ under the ticker symbol INVA.
Innoviva has made 2 acquisitions, including Entasis Therapeutics, and La Jolla Pharmaceutical.
Innoviva has 2 investors. Key investors include Goldman Sachs, and Moelis & Company.
Innoviva operates through Theravance Inc.